World-leading expertise in Gene and Cell Therapy

Size: px
Start display at page:

Download "World-leading expertise in Gene and Cell Therapy"

Transcription

1 Worldleading expertise in Gene and Cell Therapy Jefferies Healthcare Conference New York, June 2015

2 Disclaimer The information contained in this presentation is being supplied and communicated to you on a confidential basis solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. For the purpose of this disclaimer, presentation means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during Cohort 2 the presentation Dose meetings or any presentation Administration to which this 3 document months (UPDRS) relates. 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Although 1, n=3 reasonable care 1x has been taken to Original ensure that the facts stated Mean 27% in this presentation Mean are 30% accurate and Mean that the 29% opinions expressed are fair and reasonable, the contents of this presentation have not been formally Max. verified up to 30% by Oxford BioMedica plc (the Company ) or any other Max. person. up to 30% Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained 2, n=3 in this presentation, 2x and no reliance Original should be placed on Mean such 28% information or opinions. Mean 34% Further, the Mean information 29% in this presentation is not Max. up 53% complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation. This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares in the Company (the Securities ). The Securities have not been registered under the US Securities Act of 1933, as amended (the Securities Act ), or qualified for sale under the law of any state or other jurisdiction of the United States of America and may not be offered or sold in the United States of America except pursuant to such registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulatory body of any state or other jurisdiction of the United States of America, nor any securities regulatory body of any other country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is unlawful. This presentation is being communicated only to U.S. persons that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act. This presentation may contain forwardlooking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forwardlooking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing. By participating in this presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. 2

3 Oxford BioMedica an overview 1, n=3 1x Original Mean 27% Product Mean 34% Development + Proprietary gene and cell therapy pipeline + OXB Solutions Lentiviral vector manufacture and process development IP Ownership Lentiviral vector patents and knowhow A leading gene and cell therapy company 3

4 Corporate history and financing Spun out of Oxford University in , n=3 1x Original Mean 27% Mean 34% London Stock Exchange (Ticker OXB.L) Market capitalisation $405m (May 25, 2015) $22m cash at December 31, 2014, plus $50m loan facility 4

5 Gene therapy & cell therapy In vivo Ex vivo ProSavin (Parkinson s disease) Lentivector manufacturing for CTL019 1, n=3 1x Original Mean 27% Mean 34% RetinoStat (Wet AMD) 5

6 Lentiviral vector advantages over AAV 1. Larger therapeutic payloads 2. Permanent modification of dividing cells such as Tcells or 1, n=3 1x Original Mean 27% stem cells Mean 34% Potential for one shot treatment giving longterm or permanent efficacy 6

7 Oxford BioMedica s unique capabilities Slide for large image Proprietary analytics Analytical development Lentiviral vector IP OXB Solutions Process development Cell/Vector engineering Manufacturing capacity One stop shop 7

8 Oxford BioMedica s business model Product pipeline + OXB process development 1, n=3 1x Original Mean 27% Development Solutions IP Ownership + Mean 34% Lentiviral vector Lentiviral vector Proprietary gene manufacture and patents and know 3, n=3 and cell therapy 2x Enhanced Mean 26% how Revenues Manufacturing and process development Licence fees Milestones Royalties 8

9 Product Portfolio Oxford BioMedica 2011, all rights reserved 9

10 Portfolio of pipeline assets (excluding those already outlicensed) Lentiviral vector TECHNOLOGY Product Indication Stage Next inflection 1, n=3 1x Original Mean 27% OPHTHALMOLOGY RetinoStat Wet AMD Phase I follow up stage Mean 34% (primary end point met) Est. date Phase I CSR 2015 EncorStat Corneal graft rejection Phase I/II preparation FPI Phase I/II 2016 GlaucomaGT Chronic glaucoma Preclinical End preclinical 2016 CNS ProSavin OXB102 Parkinson s disease Phase I/II complete Phase I/II preparation FPI Phase I/II 2016 MoNuDin Motor neuron disease Research End preclinical 2015 NEW IDEAS 5T4 TECHNOLOGY Investigating several therapy areas where Lenti based vectors have an advantage over AAV due to payload capacity Exploring possibilities to enter cell therapy field in our own right e.g. CART 5T4 ONCOLOGY TroVax Cancer (multiple) 3 x Phase II ongoing End Phase II 2015/16 CART 5T4 Cancer (multiple) Preclinical End preclinical 2016 TBD TBD 10

11 Licences to OXB s IP and products 1, n=3 Company 1x Products Original Terms Mean 27% Lenti based vector IP & Knowhow Novartis CTL019/ Other CART $10m Max. up to upfront 53% Mean 34% Estimated launch date 2017 Multi billion $ GSK Up to 6 rare orphan diseases Undisclosed royalties Products Sanofi StarGen Undisclosed development milestones and royalties 5T4 Tumour antigen Estimated Peak Yr Sales Not disclosed TBD $10m $50m per product 2021 $500m Sanofi UshStat 2021 $90m IP Pfizer 5T4 antibody Undisclosed 2023 >$300m IP ImaginAb 5T4 imaging diagnostic PrimeBoost Undisclosed 2024 $10m IP Bavarian Nordic PROSTVAC TM Undisclosed 2017 $60m 11

12 Gamechanging Novartis contract Nonexclusive licence to OXB s IP 1, n=3 1x Original Mean 27% Initial 3 year manufacturing contract for clinical supply for NVS CTL019 Mean 34% programme potential to extend Process development collaboration Financial terms include $14m up front, including an equity investment and IP licence Undisclosed royalties on CTL019 and other CART products Up to $76m over 3 year manufacturing and process development 2014 Transforming cash flows 12

13 Expanding facilities Windrush Court Corporate Headquarters & Laboratories Harrow House (GMP1/GMP2/GMP3) Fill & Finish API manufacturing facility Yarnton (GMP4) API manufacturing facility 13

14 Financial position Cash at end m 1, n=3 1x Original Mean 27% $50m loan facility secured May 2015 Mean 34% $25m drawn down 3m AMSCI loan repaid and facility terminated Capital expenditure across 2015/2016 expected to be in the region of 20m Manufacturing and process development revenues set to grow in 2015, reducing underlying operational cash burn 14

15 Upcoming potential value driving news flow 2015 Further IP licences/manufacturing/process development contracts 1, n=3 1x RetinoStat Original decision Mean regarding 27% Mean Phase 30% II Mean indication 29% and development pathway Mean 34% Identification of new product development candidates TroVax Phase II studies initial results 2016 MoNuDin preclinical results FPI OXB102 clinical programme FPI EncorStat clinical programme StarGen /UshStat development milestones GlaucomaGT preclinical results CART 5T4 preclinical results Plus updates from Novartis on CTL019 programme from time to time 15

16 In summary Whollyowned highvalue clinical pipeline for value generation Three gene therapy product candidates in Phase I/II development Three investigatorled Phase II TroVax studies 1, n=3 1x Original Mean 27% Outlicensed clinical programmes Mean 34% Two ophthalmology in vivo Phase I/II products licensed to Sanofi Two outlicensed 5T4 antibody technology phase I studies Further innovative product development opportunities for value creation Including CART 5T4 Lentiviral vector IP recognised by Novartis, GSK Significant revenue potential from manufacturing and process development offsets cash burn 16

17 Contact us Oxford BioMedica plc 1, Windrush n=3 Court 1x Original Mean 27% Tim Watts, CFO Transport Way Oxford OX4 6LT United Kingdom John Dawson, CEO Tel: +44 (0) Mean 34%

Oxford BioMedica. Annual Results 2008

Oxford BioMedica. Annual Results 2008 Oxford BioMedica Annual Results 2008 12 March 2009 Disclaimer This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the Securities ). Although reasonable

More information

2010/OB/07 EMBARGOED UNTIL 7.00AM 10 MARCH 2010 10 MARCH 2010 OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2009

2010/OB/07 EMBARGOED UNTIL 7.00AM 10 MARCH 2010 10 MARCH 2010 OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2009 2010/OB/07 EMBARGOED UNTIL 7.00AM 10 MARCH 2010 10 MARCH 2010 OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2009 Oxford, UK 10 March 2010: Oxford BioMedica (LSE: OXB), a leading

More information

20.2m Net cash 3 : (H1 2010: 16.3 million). + 20m Fundraising: 20 million before expenses, completed 10 January 2011. Highlights

20.2m Net cash 3 : (H1 2010: 16.3 million). + 20m Fundraising: 20 million before expenses, completed 10 January 2011. Highlights Interim Report 2011 Our journey is about discovery. New medicines and treatments that could improve life for millions of people. By realising these discoveries we will fight life-threatening and debilitating

More information

FONDUL PROPRIETATEA S.A.

FONDUL PROPRIETATEA S.A. To: Bucharest Stock Exchange Financial Supervisory Authority Current report according to Article 99 of the Code of the Bucharest Stock Exchange, Title II, Issuers and Financial Instruments. Events to be

More information

Our centre of excellence. World class expertise, capabilities and facilities in GMP manufacturing

Our centre of excellence. World class expertise, capabilities and facilities in GMP manufacturing Our centre of excellence World class expertise, capabilities and facilities in GMP manufacturing Our corporate profile Oxford BioMedica is a world leader in the development of innovative treatments to

More information

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Disclaimer The information contained in this presentation ( Presentation ) has been prepared by Firestone Diamonds plc (the

More information

How To Sell A Share In Amsterdam Molecular Therapy

How To Sell A Share In Amsterdam Molecular Therapy NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Gjensidige Insurance Group Q4 2008 and preliminary 2008

Gjensidige Insurance Group Q4 2008 and preliminary 2008 Gjensidige Insurance Group Q4 2008 and preliminary 2008 Disclaimer The information contained herein has been prepared by and is the sole responsibility of Gjensidige Forsikring BA ( the Company ). Such

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

SBERBANK GROUP S IFRS RESULTS. March 2015

SBERBANK GROUP S IFRS RESULTS. March 2015 SBERBANK GROUP S IFRS RESULTS 2014 March 2015 SUMMARY OF PERFORMANCE FOR 2014 STATEMENT OF PROFIT OR LOSS Net profit reached RUB 290.3bn (or RUB 13.45 per ordinary share), compared to RUB 362.0bn (or RUB

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa

DNB Markets 5 th Annual Health Care Conference, 11 December 2014 CEO Luigi Costa DNB Markets 5 th Annual Health Care Conference, December 0 CEO Luigi Costa Nordic Nanovector ASA Kjelsåsveien 68 B, 088 Oslo, Norway - www.nordicnanovector.com Forward-looking statements This presentation

More information

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors 28 January 2015 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES.

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

ING (US) ISSUANCE LLC REGISTRATION DOCUMENT

ING (US) ISSUANCE LLC REGISTRATION DOCUMENT Dated 15 May 2009 ING (US) ISSUANCE LLC REGISTRATION DOCUMENT Table of Contents Page INTRODUCTION... 1 DOCUMENTS INCORPORATED BY REFERENCE... 3 RISK FACTORS... 4 DESCRIPTION OF ING (US) ISSUANCE LLC....

More information

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO April 2016 Bruno Jactel, CEO Erica Boisvert, CFO OUR MISSION TYRATECH Is a life science technology company focused on: pesticide-free products to control insects and parasites 1 ton of pesticide per person/year!

More information

pressrelease ROCKET INTERNET PRICES IPO AT TOP OF PRICE RANGE MANILA, Philippines, 2 nd October 2014 - Philippine Long Distance Telephone Company ( PLDT ) (PSE:TEL) (NYSE:PHI), the leading telecoms operator

More information

Update following the publication of the Bank of England Stress Test. 16 December 2014

Update following the publication of the Bank of England Stress Test. 16 December 2014 Update following the publication of the Bank of England Stress Test 16 December 2014 Background Top 8 Banks Resilience Stress Tested by PRA following FPC recommendation in March 2013 Guidance for stress

More information

Terms of Use & Privacy Policy

Terms of Use & Privacy Policy Terms of Use & Privacy Policy These terms and conditions apply to your access and use of the Registration website and the Live Streaming website to UOB Privilege Conversations Live Webcast(collectively

More information

Sberbank Group s IFRS Results for 6 Months 2013. August 2013

Sberbank Group s IFRS Results for 6 Months 2013. August 2013 Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB

More information

F. van Lanschot Bankiers N.V. (incorporated in the Netherlands with its statutory seat in 's-hertogenbosch)

F. van Lanschot Bankiers N.V. (incorporated in the Netherlands with its statutory seat in 's-hertogenbosch) 20 December 2012 FIFTH SUPPLEMENT TO THE BASE PROSPECTUS IN RESPECT OF THE EURO 5,000,000,000 DEBT ISSUANCE PROGRAMME F. van Lanschot Bankiers N.V. (incorporated in the Netherlands with its statutory seat

More information

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM

Tungsten Corporation PLC. Successful placing to raise 160 million significantly over subscribed. Admission to Trading on AIM NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT

More information

Nord Gold N.V. Separation. December 5, 2011. London

Nord Gold N.V. Separation. December 5, 2011. London Nord Gold N.V. Separation December 5, 2011. London Disclaimer Page 2 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, THE RUSSIAN FEDERATION OR ANY JURISDICTION WHERE TO DO SO WOULD VIOLATE

More information

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global

More information

TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES. Presenting at Småbolagsdagen June 10, 2013

TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES. Presenting at Småbolagsdagen June 10, 2013 TRANSITION TO A COMMERCIAL AND PROFITABLE PHARMACEUTICAL COMPANY CONTINUES Presenting at Småbolagsdagen June 10, 2013 LEGAL DISCLAIMER This presentation, which is personal to the recipient, has been prepared

More information

Analysts & Press Presentation. Fabrizio Viola - CEO Bernardo Mingrone - CFO

Analysts & Press Presentation. Fabrizio Viola - CEO Bernardo Mingrone - CFO Analysts & Press Presentation Fabrizio Viola - CEO Bernardo Mingrone - CFO Siena 24 th September 2015 Executive Summary Settlement agreement with Nomura on the Alexandria transaction Closing of the last

More information

Certain technical and administrative guidelines with regard to the public-to-private and financing transaction between

Certain technical and administrative guidelines with regard to the public-to-private and financing transaction between Certain technical and administrative guidelines with regard to the public-to-private and financing transaction between Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation ISIN Code NL0000886968

More information

2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04

2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04 2018-04 SEK ING Sprinter Sverige ING Bank NV (NL) 20 Units Outperformance Bonus Certificates linked to OMX due 2018-04 Product Description This 5YR SEK Outperformance Bonus Certificate is linked to the

More information

Intertrust N.V. announces the indicative price range, offer size, start of offer period and publication of prospectus of its planned IPO

Intertrust N.V. announces the indicative price range, offer size, start of offer period and publication of prospectus of its planned IPO This press release and the information contained herein are not for distribution in or into the United States of America (including its territories and possessions, any state of the United States of America

More information

SUNDARAM ASSET MANAGEMENT

SUNDARAM ASSET MANAGEMENT SUNDARAM ASSET MANAGEMENT 1 Quick background Headquartered in Chennai (India) with offices in Singapore and Dubai Wholly owned by the prestigious Sundaram Finance Limited Has 17 years of experience in

More information

LICENCE FOR EMPLOYMENT APPLICATION. means Eversheds LLP whose registered office is at One Wood Street, London EC2V 7WS.

LICENCE FOR EMPLOYMENT APPLICATION. means Eversheds LLP whose registered office is at One Wood Street, London EC2V 7WS. LICENCE FOR EMPLOYMENT APPLICATION 1. DEFINITIONS Eversheds Licensee Application Intellectual Property Rights Use means Eversheds LLP whose registered office is at One Wood Street, London EC2V 7WS. means:

More information

Galapagos reports largest cash balance ever

Galapagos reports largest cash balance ever Regulated information 3 March 2016, 22.00 CET Galapagos reports largest cash balance ever Key 2015 financials: Cash burn of 122 million, in line with guidance Cash balance on 31 December 2015 of 348 million

More information

Ubiquitous secure file sharing on any device

Ubiquitous secure file sharing on any device Ubiquitous secure file sharing on any device This presentation is not an offer to sell or a solicitation of an offer to purchase securities by Zyber Secure Mobile Solutions Inc. ( Zyber ). Any such offer

More information

Partners in Care Welch Allyn Connex Software Development Kit License Agreement

Partners in Care Welch Allyn Connex Software Development Kit License Agreement This Software Development Kit End User ( Agreement ) is between Welch Allyn, Inc. ( Welch Allyn ) and the Customer identified in the purchase order ( Customer or You ), and it governs the Software Development

More information

FILEMAKER PRO ADVANCED SOFTWARE LICENSE

FILEMAKER PRO ADVANCED SOFTWARE LICENSE FILEMAKER PRO ADVANCED SOFTWARE LICENSE IMPORTANT -- READ CAREFULLY: BY INSTALLING, COPYING, DOWNLOADING, ACCESSING OR OTHERWISE USING THE SOFTWARE, YOU AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE.

More information

Smart Metering Systems plc. Interim Results For the half year ended 30 June 2015

Smart Metering Systems plc. Interim Results For the half year ended 30 June 2015 Smart Metering Systems plc Interim Results For the half year ended 2015 Introduction and agenda Business review Alan Foy, CEO SMS story Financial Operational Financial review Glen Murray, CFO Highlights

More information

Scancell Holdings plc ( Scancell Holdings or the Company )

Scancell Holdings plc ( Scancell Holdings or the Company ) Release Date: 29 January 2010 GB00B39J5N63 Scancell Holdings plc ( Scancell Holdings or the Company ) Interim Results for the six month period to 31 Scancell (SCLP.PL), the developer of therapeutic cancer

More information

Presentation to Dockwise. 24 April 2012

Presentation to Dockwise. 24 April 2012 Presentation to Dockwise 24 April 2012 Disclaimer This presentation has been prepared by Fairstar Heavy Transport NV ( FHT or the company ). This presentation is for information purposes only. This presentation

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

CONTRIBUTION AGREEMENT of INCROWD ALABAMA FUND I, LLC

CONTRIBUTION AGREEMENT of INCROWD ALABAMA FUND I, LLC CONTRIBUTION AGREEMENT of INCROWD ALABAMA FUND I, LLC INSTRUCTIONS TO INVESTORS EACH PROSPECTIVE INVESTOR IN INCROWD ALABAMA FUND I, LLC (THE COMPANY ) SHOULD EXAMINE THE SUITABILITY OF THIS TYPE OF INVESTMENT

More information

STOCK PURCHASE AGREEMENT

STOCK PURCHASE AGREEMENT STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this Agreement ) is made as of, 2015, by and between Histogen Inc., a Delaware corporation (the Company ), and (hereinafter referred to as the Investor

More information

Fourth Quarter 2014. Published February 25, 2015. www.asetek.com

Fourth Quarter 2014. Published February 25, 2015. www.asetek.com Fourth Quarter 2014 Published February 25, 2015 Disclaimer This presentation and its enclosures and appendices (jointly referred to as the Presentation ) has been produced by Asetek A/S (the Company )

More information

P. H. Glatfelter Company (Exact name of registrant as specified in its charter)

P. H. Glatfelter Company (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

Company Profile // May 2012

Company Profile // May 2012 Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for

More information

Company Name, Address. Material Transfer Agreement for SUBJECT

Company Name, Address. Material Transfer Agreement for SUBJECT DATED: BETWEEN: AIMM Therapeutics BV Meibergdreef 59 1105 BA Amsterdam The Netherlands and Company Name, Address Material Transfer Agreement for SUBJECT THE UNDERSIGNED, Material Transfer Agreement for

More information

National Credit Default Rates Continued Their Upward Trend in December 2014 According to the S&P/Experian Consumer Credit Default Indices

National Credit Default Rates Continued Their Upward Trend in December 2014 According to the S&P/Experian Consumer Credit Default Indices National Credit Default Rates Continued Their Upward Trend in December 2014 According to the S&P/Experian Consumer Credit Default Indices Four of the Five Cities Saw Default Rates Increase in December

More information

Gjensidige in brief. Attractive position in Nordic GI. Balanced retail portfolio. Private and SME exposure 80 % direct distribution

Gjensidige in brief. Attractive position in Nordic GI. Balanced retail portfolio. Private and SME exposure 80 % direct distribution 1 Gjensidige in brief Attractive position in Nordic GI Balanced retail portfolio Accident & Health 21% Motor 33% Property 36% 200 years history Earned premiums : NOK bn 19 Equity: NOK bn 26 Market cap:

More information

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based

More information

Investor presentation

Investor presentation Public Company Limited Investor presentation February 2013 Page 0 Disclaimer This presentation is the sole responsibility of the directors of Urals Energy PCL (the Company ). Allenby Capital Limited (

More information

African Barrick Gold. BMO Global Metals & Mining Conference February 2013

African Barrick Gold. BMO Global Metals & Mining Conference February 2013 African Barrick Gold BMO Global Metals & Mining Conference February 2013 Disclaimer Important Notice This presentation has been provided to you for information purposes only. It does not constitute an

More information

2014 FIRST QUARTER RESULTS CONFERENCE CALL. May 15th, 2014

2014 FIRST QUARTER RESULTS CONFERENCE CALL. May 15th, 2014 2014 FIRST QUARTER RESULTS CONFERENCE CALL May 15th, 2014 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces

More information

Publication and posting of the Very Substantial and Connected Acquisition Circular and Scheme Document

Publication and posting of the Very Substantial and Connected Acquisition Circular and Scheme Document (Incorporated in the Cayman Islands with Limited Liability) Stock Code: 0575 4 February 2016 ANNOUNCEMENT This announcement is not for release, publication or distribution in whole or in part in or into

More information

Proposal to Build the First Truly Global Beer Company October 7, 2015

Proposal to Build the First Truly Global Beer Company October 7, 2015 Proposal to Build the First Truly Global Beer Company October 7, 2015 Disclaimer NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD

More information

Trinity Online Application - Terms and Conditions of Use

Trinity Online Application - Terms and Conditions of Use IMPORTANT NOTICE PLEASE READ THE FOLLOWING TERMS AND CONDITIONS CAREFULLY. IF YOU DO NOT AGREE WITH THESE TERMS AND CONDITIONS, YOU MUST NOT USE THIS APPLICATION. BY USING THIS APPLICATION AND/OR ANY OF

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

XXL ASA - Announcement of terms in the Initial Public Offering

XXL ASA - Announcement of terms in the Initial Public Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF

More information

RESULTS FIRST QUARTER 2015

RESULTS FIRST QUARTER 2015 0 April 27, 2015 RESULTS FIRST QUARTER 2015 An integrated energy player focused on exploration and production DISCLAIMER 1 RCA figures except otherwise noted. By attending or reading this presentation,

More information

SUBSCRIPTION AGREEMENT INSTRUCTIONS. If you wish to subscribe for Units in the Offering, you should take each of the following steps:

SUBSCRIPTION AGREEMENT INSTRUCTIONS. If you wish to subscribe for Units in the Offering, you should take each of the following steps: SUBSCRIPTION AGREEMENT INSTRUCTIONS How to Subscribe If you wish to subscribe for Units in the Offering, you should take each of the following steps: General Instructions Print, complete and sign the Subscription

More information

Interim report Second quarter 2015

Interim report Second quarter 2015 Interim report Second quarter 2015 Oslo, 20 August 2015 Presenters and agenda Agenda Hans-Petter Mellerud Founder and CEO Highlights for the quarter Financial performance Regional trends Nina Stemshaug

More information

2015 FIRST HALF RESULTS CONFERENCE CALL. August 31st, 2015

2015 FIRST HALF RESULTS CONFERENCE CALL. August 31st, 2015 2015 FIRST HALF RESULTS CONFERENCE CALL August 31st, 2015 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The

More information

Pharming Group NV (Euronext: PHARM)

Pharming Group NV (Euronext: PHARM) Pharming Group NV (Euronext: PHARM) Sijmen de Vries, MD, MBA Chief Executive Officer Annual General Meeting of Shareholders Leiden, 30 April 2015 1 Safe harbour statement The information contained in this

More information

Launch Announcement for Warrants to be issued by

Launch Announcement for Warrants to be issued by This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Warrants described below. Hong Kong Exchanges and Clearing

More information

PDL BioPharma Announces Third Quarter 2015 Financial Results

PDL BioPharma Announces Third Quarter 2015 Financial Results November 4, 2015 PDL BioPharma Announces Third Quarter 2015 Financial Results INCLINE VILLAGE, Nev., Nov. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results

More information

Terms & Conditions Governing UOB Income Builder Dreams Promotion (6 July 2015 2 August 2015) ( Promotion )

Terms & Conditions Governing UOB Income Builder Dreams Promotion (6 July 2015 2 August 2015) ( Promotion ) Terms & Conditions Governing UOB Income Builder Dreams Promotion (6 July 2015 2 August 2015) ( Promotion ) 1. Introduction 1.1 The Promotion shall commence from 06 July 2015 to 02 August 2015 (both dates

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Hoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm

Hoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Press release Stockholm 26 February 2015 Hoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Hoist Finance AB (publ) ( Hoist Finance or the Company

More information

THE BUSINESS COUNCIL OF WESTCHESTER Website & Internet Services Terms And Conditions of Use

THE BUSINESS COUNCIL OF WESTCHESTER Website & Internet Services Terms And Conditions of Use THE BUSINESS COUNCIL OF WESTCHESTER Website & Internet Services Terms And Conditions of Use PLEASE READ THE FOLLOWING TERMS AND CONDITIONS RELATING TO YOUR USE OF OUR WEBSITE AND ANY OTHER INTERNET-BASED

More information

Sample Private Placement Memorandum

Sample Private Placement Memorandum Sample Private Placement Memorandum Jean E. Harris Greenberg Traurig, LLP Phoenix, AZ Private Placement Memorandum Copy No. ABC CORPORATION 1,250,000 Shares SERIES 1 CONVERTIBLE PREFERRED STOCK $2.00 per

More information

Factsheet Phoenix Autocallable Notes April 2012

Factsheet Phoenix Autocallable Notes April 2012 This information is intended for investment professionals only and should not be provided to or relied upon by retail investors in any circumstances. Investment Guide for Income Builder December 2011 www.gilliat.co.uk

More information

IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S

IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. EXCEPT TO QUALIFIED INSTITUTIONAL BUYERS (AS DEFINED BELOW) IMPORTANT: You must read the following before

More information

GlaxoSmithKline Single Sign On Portal for ClearView and Campaign Tracker - Terms of Use

GlaxoSmithKline Single Sign On Portal for ClearView and Campaign Tracker - Terms of Use GlaxoSmithKline Single Sign On Portal for ClearView and Campaign Tracker - Terms of Use IMPORTANT! YOUR REGISTRATION AND USE OF THIS GlaxoSmithKline Single Sign On Portal for ClearView and Campaign Tracker

More information

2015 GROUP COMPENSATION POLICY SIDE PRESENTATION. 13 April 2015 UniCredit Human Resources Strategy

2015 GROUP COMPENSATION POLICY SIDE PRESENTATION. 13 April 2015 UniCredit Human Resources Strategy 2015 GROUP COMPENSATION POLICY SIDE PRESENTATION 13 April 2015 UniCredit Human Resources Strategy OBJECTIVE OF THE DOCUMENT The purpose of this presentation is to provide an overview of the key elements

More information

Important Disclosures

Important Disclosures Company Overview Important Disclosures This presentation contains forward-looking statements, including financial and other information relating to First Physicians Capital Group, Inc. ( FPCG or the Company

More information

Spark Advisors Advisory Agreement

Spark Advisors Advisory Agreement Spark Advisors Advisory Agreement This Investment Advisor Agreement ( Agreement ) is by and between Spark Advisors, LLC ( Spark Advisors or Adviser ), a registered investment adviser, and the party electronically

More information

Rating Action: Moody's assigns Aaa.br rating to Duke's BRL479 million debentures; outlook stable

Rating Action: Moody's assigns Aaa.br rating to Duke's BRL479 million debentures; outlook stable Rating Action: Moody's assigns Aaa.br rating to Duke's BRL479 million debentures; outlook stable Global Credit Research - 11 Apr 2014 Approximately BRL1.1 billion of debt instruments affected Sao Paulo,

More information

Requester Name: Email Address: Mailing address: US Mail: International or Express Mail:

Requester Name: Email Address: Mailing address: US Mail: International or Express Mail: National Stem Cell Bank Following is a check-list for submitting agreements from ES Cell International to the National Stem Cell Bank (NSCB) for human embryonic stem cells. Create an account on the NSCB

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

Magellan Global Equities Fund An Innovative Vehicle for Global Equity Investors

Magellan Global Equities Fund An Innovative Vehicle for Global Equity Investors Magellan Global Equities Fund An Innovative Vehicle for Global Equity Investors March 2015 Important Information This presentation ( Presentation ) has been produced by Magellan Asset Management Limited

More information

CENTURY 21 CANADA LIMITED PARTNERSHIP WEBSITE TERMS OF USE

CENTURY 21 CANADA LIMITED PARTNERSHIP WEBSITE TERMS OF USE CENTURY 21 CANADA LIMITED PARTNERSHIP WEBSITE TERMS OF USE THESE TERMS OF USE CONTAIN LEGAL OBLIGATIONS. PLEASE READ THESE TERMS OF USE BEFORE USING THIS WEBSITE. Acceptance of these Terms of Use and any

More information

The Options Clearing Corporation

The Options Clearing Corporation PROSPECTUS M The Options Clearing Corporation PUT AND CALL OPTIONS This prospectus pertains to put and call security options ( Options ) issued by The Options Clearing Corporation ( OCC ). Certain types

More information

Sopra Group announces the accounting impact of the exceptional cash distribution and of the distribution of Axway Software shares

Sopra Group announces the accounting impact of the exceptional cash distribution and of the distribution of Axway Software shares Press Release Contacts Investor Relations: Kathleen Clark Bracco +33 (0)1 40 67 29 61 kbraccoclark@sopragroup.com Press Relations: Virginie Legoupil +33 (0)1 40 67 29 41 vlegoupil@sopragroup.com Image

More information

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION RUNNINGBALL ACQUISITION INVESTOR PRESENTATION TRANSACTION HIGHLIGHTS Proposed acquisition of RunningBall group, a leading provider of real-time sports data to the online sports betting sector Consideration

More information

Telio & NextGenTel. NextGenTel Holding ASA. Q1 2015 Presentation. Eirik Lunde, CEO. Felix Konferansesenter Oslo 7 May 2015

Telio & NextGenTel. NextGenTel Holding ASA. Q1 2015 Presentation. Eirik Lunde, CEO. Felix Konferansesenter Oslo 7 May 2015 Telio & NextGenTel NextGenTel Holding ASA Q1 215 Presentation Eirik Lunde, CEO Felix Konferansesenter Oslo 7 May 215 This is NextGenTel Group Background Telio Pioneer in the Norwegian VoIP market rapid

More information

FOR IMMEDIATE RELEASE 10 July 2006 RECOMMENDED FINAL OFFERS * AIRPORT DEVELOPMENT AND INVESTMENTLIMITED. a company held by

FOR IMMEDIATE RELEASE 10 July 2006 RECOMMENDED FINAL OFFERS * AIRPORT DEVELOPMENT AND INVESTMENTLIMITED. a company held by FOR IMMEDIATE RELEASE 10 July 2006 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO CANADA RECOMMENDED FINAL OFFERS * by AIRPORT DEVELOPMENT AND INVESTMENTLIMITED a company

More information

Benchmarking for Australia s Superannuation Funds

Benchmarking for Australia s Superannuation Funds Benchmarking for s Superannuation Funds Guide to the Index Series The Index Series, a partnership between and the Association of Superannuation Funds of (ASFA), is designed to address the requirement of

More information

Petrel Energy Ltd. This report is intended for CCMInternalDistribution@clarksons.com. Unauthorized redistribution of this report is prohibited.

Petrel Energy Ltd. This report is intended for CCMInternalDistribution@clarksons.com. Unauthorized redistribution of this report is prohibited. Exploration and Production Equity Research July 30, 2013 Crikey! Aussie Microcap Exploring Unconventional Resources on 3 Continents The smallest of our coverage companies, with exploration assets in Uruguay,

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

CALIFORNIA CAPITAL INVESTORS, LLC (a Delaware Limited Liability Company) SUBSCRIPTION AGREEMENT

CALIFORNIA CAPITAL INVESTORS, LLC (a Delaware Limited Liability Company) SUBSCRIPTION AGREEMENT CALIFORNIA CAPITAL INVESTORS, LLC (a Delaware Limited Liability Company) SUBSCRIPTION AGREEMENT To: John R. Nelson, Managing Member California Capital Investors, LLC 700 East Redlands Boulevard, #105 Redlands,

More information

Additional information AQR & Stress Test October 26, 2014

Additional information AQR & Stress Test October 26, 2014 LOCAL EXPERTISE MEETS GLOBAL EXCELLENCE Additional information AQR & Stress Test October 26, 2014 Comprehensive assessment: AQR and Stress Test Definitions The comprehensive assessment is a financial health

More information

Terms and Conditions. 3012436v2 12285.01010

Terms and Conditions. 3012436v2 12285.01010 Terms and Conditions ACCEPTANCE. Except as otherwise agreed in a written agreement signed by both parties, these Terms and Conditions will govern Buyer s purchase order. BI Technologies acceptance of Buyer

More information

Not for distribution in the United States, Canada, Australia or Japan

Not for distribution in the United States, Canada, Australia or Japan The distribution of this press release, directly or indirectly, in or into the United States, Canada, Australia or Japan is prohibited. This press release (and the information contained herein) does not

More information

THIS PROSPECTUS AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. 1 3) 2007 1995 2000 ( FSMA

THIS PROSPECTUS AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. 1 3) 2007 1995 2000 ( FSMA THIS PROSPECTUS AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to consult immediately,

More information

Acquisition of Westdeutsche ImmobilienBank AG

Acquisition of Westdeutsche ImmobilienBank AG LOCAL EXPERTISE MEETS GLOBAL EXCELLENCE Acquisition of Westdeutsche ImmobilienBank AG February, 22 nd 2015 Dr. Wolf Schumacher, CEO Hermann J. Merkens, CFO Agenda Strategic rationale Transaction structure

More information

Affitech A/S reports financial result for the first six months of 2012

Affitech A/S reports financial result for the first six months of 2012 Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for

More information

We suggest you retain a copy of these End User Terms of Use for your records.

We suggest you retain a copy of these End User Terms of Use for your records. END USER TERMS OF USE The use of Incident Response Technologies Inc. s ("IRT") Software is offered to you upon your acceptance of these End User Terms of Use. By using IRT s software (the Software ), you

More information

Kuehne + Nagel International AG Analyst Conference Call Q1 Results 2014

Kuehne + Nagel International AG Analyst Conference Call Q1 Results 2014 Kuehne + Nagel International AG Analyst Conference Call Q1 Results 2014 April 14, 2014 Schindellegi, Switzerland Forward-Looking Statements This presentation contains forward-looking statements. Such statements

More information